SEC Comment Letter 0000000000-26-005249 to Connect Biopharma Holdings Ltd (CNTB)
Connect Biopharma Holdings Ltd
Date: May 22, 2026 · CIK: 0001835268 · Accession: 0000000000-26-005249
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295921
Letter
May 22, 2026 Barry Quart Chief Executive Officer Connect Biopharma Holdings Limited 3580 Carmel Mountain Road, Suite 200 San Diego, CA 92130 Re: Connect Biopharma Holdings Limited Registration Statement on Form F-3 Filed May 15, 2026 File No. 333-295921 Dear Barry Quart: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael Sullivan
Show Raw Text
May 22, 2026 Barry Quart Chief Executive Officer Connect Biopharma Holdings Limited 3580 Carmel Mountain Road, Suite 200 San Diego, CA 92130 Re: Connect Biopharma Holdings Limited Registration Statement on Form F-3 Filed May 15, 2026 File No. 333-295921 Dear Barry Quart: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael Sullivan